What is Merck's biggest product?

Merck’s Blockbuster Drugs: Leading Innovation in Global Healthcare

When it comes to pharmaceutical powerhouses, Merck stands out with a portfolio anchored in science and patient impact. While the company develops a wide range of treatments, its biggest product by far is Keytruda, a groundbreaking immunotherapy for cancer.

Developed to harness the body’s immune system to fight tumors, Keytruda has become a cornerstone in treating various forms of cancer, including melanoma and non-small cell lung cancer. Since its approval, it has consistently topped Merck’s sales charts, generating tens of billions in annual revenue. Its success isn’t just financial—it’s reshaping how oncologists approach cancer treatment, offering hope where options were once limited.

But Keytruda isn’t alone in Merck’s lineup. Gardasil, the vaccine that protects against human papillomavirus (HPV), continues to make waves in preventive medicine. By significantly reducing the risk of cervical and other HPV-related cancers, Gardasil has become a global public health tool, widely adopted in vaccination programs around the world.

Then there’s Januvia and Janumet, Merck’s diabetes franchise. These medications help manage type 2 diabetes by regulating blood sugar levels, offering millions a more manageable daily life. While newer therapies are emerging, Januvia and its combination form Janumet remain widely prescribed, contributing substantially to the company’s revenue.

Together, these three powerhouses—Keytruda, Gardasil, and Januvia/Janumet—showcase Merck’s strength in both innovation and execution. They reflect a company that doesn’t just respond to medical needs but anticipates them. As of 2025, Merck continues to build on this legacy, investing in research that pushes the boundaries of what medicine can achieve. The future, it seems, is already in motion.